Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine.
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000201:enzymology*; D001923:Brain Chemistry / Q000187:drug effects; D003010:Clorgyline / Q000494:pharmacology; D003641:Deamination; D004298:Dopamine / Q000378:metabolism* / Q000502:physiology; D004347:Drug Interactions; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects; D009638:Norepinephrine / Q000378:metabolism; D051381:Rats; D012701:Serotonin / Q000378:metabolism* / Q000502:physiology; D013997:Time Factors; D014191:Tranylcypromine / Q000494:pharmacology; D014364:Tryptophan / Q000494:pharmacology
D008996:Monoamine Oxidase Inhibitors; D012701:Serotonin; D014191:Tranylcypromine; D007980:Levodopa; D014364:Tryptophan; D008995:Monoamine Oxidase; D003010:Clorgyline; D004298:Dopamine; D009638:Norepinephrine